hepatocellular carcinoma (HCC)
Conditions
Interventions
High HAC group/Low HAC group:None
Sponsors
The Second Affiliated Hospital of Kunming Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Clinical diagnosis of HCC according to the NHLBI Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 edition), or diagnosis of HCC by liver puncture biopsy or postoperative pathology, and preoperative hepatocellular carcinoma BCLC stage 0-A; (2) Preoperative liver function Child-pugh classification is grade A or B, with no obvious contraindication to surgery; (3) Received radical hepatectomy treatment; (4) Not having received systemic treatments such as hepatic artery chemoembolization, hepatic artery embolization, hepatic artery perfusion chemotherapy, local treatment with percutaneous anhydrous ethanol injection therapy, or targeted immunization before surgery; (5) Triple-phase CT scan within 2 weeks prior to surgery.
Exclusion criteria
Exclusion criteria: (1) Patients with complete occlusion of the main portal vein trunk, or with arteriovenous leakage; (2) Cases if the peak aortic enhancement is not in the arterial phase or the peak portal vein enhancement is not in the venous phase; (3) Patients with R1/R2 resection, surgery for recurrent HCC, or malignant tumors of other organs during the same period; (4) Patients with other liver diseases (e.g., Buga syndrome) and heart, brain, and kidney diseases; (5) Patients with combined HIV infection; (6) Patients with incomplete clinical information.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hepatic artery coefficient;Portal vein coefficient;total bilirubin;INR;albumin;ProthrombinTime; | — |
Countries
China
Contacts
Public ContactKe Yang
The Second Affiliated Hospital of Kunming Medical University
Outcome results
None listed